Skip to main content

Milestone Pharmaceuticals Inc.

corporate_fare Company Profile

Milestone Pharmaceuticals Inc.

MIST·NASDAQ·Life Sciences·CIK 0001408443

Milestone Pharmaceuticals Inc. is a biopharmaceutical company that develops and commercializes innovative cardiovascular medicines. The company's approved product, CARDAMYST™ (etripamil) nasal spray, is available in the United States. This product is the first and only FDA-approved self-administered treatment for patients to use anywhere, anytime an attack of paroxysmal supraventricular tachycardia (PSVT) occurs. Milestone Pharmaceuticals Inc. is also pursuing marketing approval for CARDAMYST™ in regions outside the United States, either directly or through partnerships. The company is also developing etripamil for the treatment of atrial fibrillation with rapid ventricular rate (AFib-RVR). Milestone Pharmaceuticals Inc. focuses its efforts and financial resources on three main areas: the commercialization of CARDAMYST™ (etripamil) nasal spray for PSVT, the development of etripamil for AFib-RVR, and corporate development activities aimed at increasing company value through strategic collaborations. On December 12, 2025, the FDA approved CARDAMYST™ (etripamil) nasal spray as a prescription medication for converting acute symptomatic episodes of PSVT to sinus rhythm in adults. This product became available in retail pharmacies in the first quarter of 2026. Milestone Pharmaceuticals Inc. manufactures CARDAMYST™ using a global supply chain that produces the active pharmaceutical ingredient, etripamil, formulates and assembles it into a nasal spray delivery device, and then packages the product. A third-party logistics provider distributes the product to wholesalers for delivery to retail pharmacies. The company's sales team of approximately 60 representatives aims to engage healthcare providers who are expected to treat around 500,000 patients diagnosed with PSVT in 2026. Milestone Pharmaceuticals Inc. designed the etripamil molecule and is commercializing and further developing this novel, potent, and rapid-onset calcium channel blocker as a patient-administered nasal spray to terminate episodes of transient cardiovascular conditions.

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for MIST at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Milestone Pharmaceuticals Closes $75M Royalty Sale, Securing Substantial Capital
  • Milestone Pharma's Etripamil Nasal Spray MAA Accepted by EMA for PSVT

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$63.06M
Diluted EPS
-$0.75
Op. Cash Flow
-$49.04M
Free Cash Flow
-$49.34M
Operating Income
-$62.14M
Cash & Equivalents
$73.05M
Total Debt
$57.19M
Debt / Equity
1.37×
Shares Outstanding
106.24M sh
Source: 10-K · filed 2026-03-20 · accession 0001104659-26-032415
$0.51 -1.92% today
52-week range · as of 2026-11-13 $0.51 – $3.06
Market cap
$64.74M
Volume
4.2M (3.2× avg)
3-mo avg 1.3M
Live data · 2026-11-16 11:21 UTC · Pre-market

show_chartPrice Chart

Loading chart...

feed MIST - Filings & News (Page 2)

MIST
Jan 13, 2026, 6:06 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.96
Real-time Price: $0.510 info
Change: -$1.45 (-74%) info
Market Cap: $64.739M info
MIST
Jan 06, 2026, 8:06 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.03
Real-time Price: $0.510 info
Change: -$1.52 (-75%) info
Market Cap: $64.739M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets